Product Description
Hoffmann-La Roche was developing ro-5027838, an oral agent for Diabetes Mellitus Type 2
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2008-001122-13 | P2 |
Completed |
Type 2 Diabetes |
2009-08-24 |
2025-06-06 |
Treatments |
|
| BP21850 | P2 |
Completed |
Type 2 Diabetes |
2009-08-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|